GlassScriptPhysician profile
Goutami Mangu
NPI 1952939951
$1,000.49
in general payments reported to CMS, 2019-2025
23 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $128.16 | 2025 | Freestyle Libre 3 |
| Dexcom, INC. | $105.45 | 2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $95.28 | 2025 | Ozempic, Wegovy |
| Insulet Corporation | $81.80 | 2025 | Omnipod |
| Radius Health, INC. | $69.28 | 2025 | Tymlos |
| Amgen INC. | $53.66 | 2025 | Tepezza |
| Amneal Pharmaceuticals LLC | $44.08 | 2025 | Unithroid |
| Madrigal Pharmaceuticals | $42.21 | 2025 | Rezdiffra |
| Corcept Therapeutics | $34.85 | 2025 | Korlym |
| Ibsa Pharma INC. | $34.20 | 2025 | Licart, Tirosint, Flector |
| Tandem Diabetes Care, INC. | $32.94 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $31.87 | 2025 | |
| Kyowa Kirin, INC. | $29.43 | 2025 | |
| Antares Pharma, INC. | $27.98 | 2025 | Xyosted |
| Neurocrine Biosciences, INC. | $27.95 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $24.83 | 2025 | Isturisa |
| Sequel Med Tech, LLC | $24.55 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $23.33 | 2025 | Gvoke Hypopen |
| Tolmar, INC. | $19.47 | 2025 | Jatenzo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.82 | 2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $18.36 | 2025 | Strensiq |
| Cequr Corporation | $17.28 | 2025 | Cequr Simplicity |
| Lilly USA, LLC | $14.71 | 2025 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Goutami Mangu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.